COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
BerGenBio is a Norway-based clinical-stage oncology biopharmaceutical developing Axl inhibitor BGB324 (Phase 1b) for AML and NSCLC and operating CellSelect™, an RNAi-based drug-target/biomarker discovery platform.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
